Globus Medical INC 10-Q quarterly reports

Globus Medical, Inc. announced its second quarter 2026 financial results, showcasing a significant increase in net sales driven by its Musculoskeletal Solutions segment, alongside strategic cost management.

Globus Medical reports strong Q1 2026 growth with net sales of $759.9 million, driven by successful integration of Nevro and robust musculoskeletal product demand.

Globus Medical reported a significant increase in net income and sales for the third quarter and first nine months of 2025, largely driven by the Nevro merger and robust Musculoskeletal Solutions performance.

Globus Medical reported a significant increase in second-quarter net income, driven by strong sales growth and a substantial bargain purchase gain from the Nevro acquisition.

Globus Medical's Q1 2025 net sales decreased slightly to $598.1 million compared to $606.7 million in Q1 2024, with operating income significantly increasing.

Globus Medical's Q3 2024 results show significant revenue growth and increased expenses, largely due to the merger with NuVasive.

Globus Medical's Q2 2024 results show significant revenue growth driven by the NuVasive merger and increased sales across both Musculoskeletal Solutions and Enabling Technologies.

Globus Medical's first quarter of 2024 saw a significant increase in revenue due to the NuVasive merger, but also a net loss due to integration costs and other factors.